FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) mechanisms to tackle the root causes of obesity. It suppresses appetite and reduces caloric intake, making it particularly effective for individuals whose OSA symptoms are exacerbated by excess weight.
The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment ... and moderate-to-severe obstructive sleep apnea, or OSA, a condition characterized ...
FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback